Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management

Novo Nordisk A/S608 enrolled

Overview

This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). Study participants will be recruited to complete self-administered online survey. The purpose of this research is to gather real-world evidence related to attitudes around systemic inflammation and specifically the awareness, perception, drivers and barriers, and use of hsCRP in clinical practice to identify systemic inflammation in people with ASCVD+CKD and HF.

Study Type

OBSERVATIONAL

Enrollment

608

Conditions

Atherosclerotic Cardiovascular Disease Heart Failure Chronic Kidney Disease

Interventions

No treatment givenOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above 18 years at the time of signing informed consent. * Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only). * Has been in specialty practice greater than or equal to 3 years. * If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month. * If nephrologist, sees at least 20 people with ASCVD and CKD per month. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * If nephrologist, is only using dialysis to treat people with ASCVD and CKD. * Does not meet inclusion criteria requirements.

Locations (4)

Novo Nordisk Investigational Site

Sydney, Australia

Novo Nordisk Investigational Site

Bangalore, Karnataka, India

Novo Nordisk Investigational Site

Seoul, South Korea

Novo Nordisk Investigational Site

Bangkok, Thailand

Outcomes

Primary Outcomes

Perceptions towards role of systemic inflammation in identification, treatment, management of ASCVD+CKD and HF

Multi-select from a defined list; 7-point Likert scale where 1=Not at all Important and Single-select from a defined list; Numerical; 7=Extremely Important; 7-point Likert scale where 1=Strongly Disagree and 7=Strongly Agree. Cardiologists and nephrologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of people with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease (ASCVD+CKD) and Heart Failure (HF)

Time frame: At the time of survey response (Day 1)